@entity12350 in XXXX : Efficacy after five years of therapy.

@entity1 @entity4051 @entity6 @entity12098 @entity2690 @entity5736 @entity4053 @entity12350 @entity413 @entity2449
UNASSIGNED: The aim of this study was to investigate whether the positive effects of @entity12350 were maintained even after five years of treatment. Starting from 2008 to today, we treated 624 @entity1 , not well controlled by current therapy, with the addition of @entity12350 100mg/die. @entity1 included 216 subjects treated with @entity2449 , 206 treated with @entity5736 , and 202 treated with @entity12098 . @entity12350 was added to @entity2449 , @entity5736 and @entity12098 in monotherapy, respectively, and the data were compared with those of 620 @entity1 treated with @entity5736 + @entity2449 , @entity12098 + @entity2449 and @entity12098 + @entity5736 matched for age, sex, @entity6 duration. We recorded that the addition of @entity12350 to current hypoglycemic therapy led to a reduction of HbA1c similar to that obtained with @entity5736 after two years. After five years of treatment, changes in @entity4051 c suggest a better glycemic control over the long term with @entity12350 compared to other treatments, particularly when compared with @entity5736 . The other parameters evaluated as fasting plasma @entity413 , post-prandial plasma @entity413 and @entity2690 levels, confirm the trends observed for the value of HbA1c. Regarding BMI, it increased with @entity5736 and @entity12098 compared to @entity12350 . @entity1 treated with @entity5736 had a higher incidence of @entity4053 compared to @entity12350 . In conclusion, @entity12350 seems to maintain its positive effects on glycemia and fasting plasma @entity2690 on the long term.
